A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: The triple oral therapy

Diabetic Medicine

Volumn 30, Issue 7, 2013, Pages 846-854

  Derosa, G ^a   Cicero, A F G ^b   Franzetti, I G ^c   Querci, F ^d   Carbone, A ^e   Piccinni, M N ^f   D'Angelo, A ^a   Fogari, E ^a   Maffioli, P ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c OSPEDALE DI CIRCOLO   (Italy)

^d Alzano Lombardo   (Italy)

^e Hospital Center of Diabetes   (Italy)

^f Fondazione Ospedale Della Caritá   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; INSULIN; METFORMIN; PIOGLITAZONE; PROINSULIN; SITAGLIPTIN;

ADULT; ARTICLE; BODY WEIGHT; CELL FUNCTION; CLINICAL PRACTICE; CONTROLLED STUDY; DIET; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG MEGADOSE; EXERCISE; FEMALE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; METFORMIN; PYRAZINES; THIAZOLIDINEDIONES; TRIAZOLES;

EID: 84879592855     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12158     Document Type: Article

References (30)

1. Weir GC, Leahy JL. Pathogenesis of non-insulin-dependent (type II) diabetes mellitus. In: Kahn CR, Weir GE, eds. Joslin's Diabetes Mellitus. 13th edition. Philadelphia: Lea & Febiger, 1994: 240-264.
2. Bogardus C. Metabolic abnormalities in the development of non-insulin-dependent diabetes mellitus. In: LeRoith D, Taylor SI, Olefski JM, eds. Diabetes Mellitus. Philadelphia: Lippincot-Raven Publishers, 1996: 459.
3. DeFronzo RA. Lilly Lecture 1987. The triumvirate: β-cell, muscle, liver. A collision responsible for NIDDM. Diabetes 1988; 37: 667-687.
4. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
6. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999; 281: 2005-2012.
7. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
8. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004; 64: 1339-1358.
9. Derosa G, Maffioli P. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 2012; 5: 272-281.
10. Derosa G. Pioglitazone is a valid alternative to rosiglitazone. Am J Cardiovasc Drugs 2011; 11: 357-362.
11. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010; 70: 1945-1961.
12. Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009; 11: 1091-1099.
13. Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, crossover, clinical trial. Curr Med Res Opin 2009; 25: 607-615.
14. Diamant M, Van Gaal L, Stranks S, Guerci B, Macconell L, Haber H et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012; 35: 683-689.
15. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
16. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA et al. Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006; 26: 2186-2191.
17. Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaventura A et al. Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. Diabetes Technol Ther 2012; 14: 475-484.
18. Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN et al. Exenatide plus metformin compared to metformin alone on β-cell function in patients with Type 2 diabetes. Diabet Med 2012; 29: 1515-1523.
19. Winer BJ. Statistical Principles in Experimental Design. 2nd edition. New York: McGraw-Hill, 1971.
20. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
21. Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP et al. Sitagliptin Study 024 Group. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562-576.
22. Arechavaleta R, Seck T, Chen Y, Krobot KJ, O'Neill EA, Duran L et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011; 13: 160-168.
23. Derosa G, Cicero AF, Fogari E, D'Angelo A, Bianchi L, Maffioli P. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Horm Metab Res 2011; 43: 505-512.
24. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010; 59: 887-895.
25. Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2012; 98: 51-60.
26. Derosa G, Carbone A, D'angelo A, Querci F, Fogari E, Cicero AFG et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. Expert Opin Pharmacother 2012; 13: 2433-2442.
27. Williams-Herman D, Xu L, Teng R, Golm GT, Johnson J, Davies MJ et al. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14: 67-76.
28. Yoon KH, Shockey GR, Teng R, Golm GT, Thakkar PR, Meehan AG et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract 2011; 65: 154-164.
29. Derosa G, Maffioli P. DPP-4 inhibitors: three years of experience. Diabetes Technol Ther 2012; 4: 350-364.
30. Derosa G, Ragonesi PD, Fogari E, Cicero AFG, Bianchi L, Bonaventura A et al. Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundam Clin Pharmacol 2012. doi: 10.1111/fcp.12001.